GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Pretax Margin %

Perspective Therapeutics (Perspective Therapeutics) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Perspective Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was $-11.83 Mil. Perspective Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Perspective Therapeutics's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Perspective Therapeutics's Pretax Margin % or its related term are showing as below:

CATX' s Pretax Margin % Range Over the Past 10 Years
Min: -141.24   Med: -79.92   Max: 2256.45
Current: 2256.45


CATX's Pretax Margin % is ranked better than
99.88% of 818 companies
in the Medical Devices & Instruments industry
Industry Median: -0.535 vs CATX: 2256.45

Perspective Therapeutics Pretax Margin % Historical Data

The historical data trend for Perspective Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics Pretax Margin % Chart

Perspective Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -70.33 -35.60 -33.69 -67.36 -

Perspective Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -701.20 -528.03 169.31 -

Competitive Comparison of Perspective Therapeutics's Pretax Margin %

For the Medical Devices subindustry, Perspective Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics's Pretax Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's Pretax Margin % falls into.



Perspective Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Perspective Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-40.106/0
= %

Perspective Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-11.825/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perspective Therapeutics  (AMEX:CATX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Perspective Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Perspective Therapeutics (Perspective Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Hills Street, Suite 106, Richland, WA, USA, 99354
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company operates two reportable business segments: Brachytherapy and Drug Operations. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.
Executives
Williamson Robert F Iii director 140 LASALLE AVENUE, PIEDMONT CA 94610
Markus Puhlmann officer: Chief Medical Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Jonathan Robert Hunt officer: Chief Financial Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Lori A Woods officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Johan M. Spoor director, officer: CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Mark John Austin officer: Controller/Prin Fin&Acct Offic 350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale director 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick director 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann director 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon officer: VP of Sales & Marketing 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline officer: Dir. of Operations, Secretary 350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter officer: VP of Human Resources 350 HILLS STREET SUITE 106, RICHLAND WA 99354